HC Wainwright Increases Aadi Bioscience (NASDAQ:AADI) Price Target to $49.00

Aadi Bioscience (NASDAQ:AADI) had its price objective raised by HC Wainwright from $47.00 to $49.00 in a research note issued to investors on Wednesday morning, Analyst Price Targets reports. They currently have a buy rating on the stock.

A number of other analysts have also recently issued reports on AADI. Zacks Investment Research cut Aadi Bioscience from a hold rating to a sell rating in a report on Monday, November 15th. Piper Sandler assumed coverage on Aadi Bioscience in a research report on Wednesday, September 8th. They set an overweight rating and a $45.00 price target on the stock. Cowen assumed coverage on Aadi Bioscience in a research report on Friday, October 1st. They set an outperform rating on the stock. Finally, LADENBURG THALM/SH SH assumed coverage on Aadi Bioscience in a research report on Tuesday, September 14th. They set a buy rating and a $51.00 price target on the stock. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Aadi Bioscience presently has an average rating of Buy and a consensus price target of $40.80.

Shares of NASDAQ:AADI opened at $22.91 on Wednesday. Aadi Bioscience has a 1 year low of $14.31 and a 1 year high of $49.80. The stock has a market capitalization of $478.68 million, a P/E ratio of -1.71 and a beta of 1.45. The stock has a 50-day simple moving average of $26.53 and a 200-day simple moving average of $24.45.

Several institutional investors and hedge funds have recently made changes to their positions in AADI. Avoro Capital Advisors LLC acquired a new position in shares of Aadi Bioscience in the 2nd quarter valued at approximately $7,605,000. RA Capital Management L.P. acquired a new position in shares of Aadi Bioscience in the 2nd quarter valued at approximately $4,552,000. VR Adviser LLC acquired a new position in shares of Aadi Bioscience in the 3rd quarter valued at approximately $44,919,000. Citadel Advisors LLC raised its position in shares of Aadi Bioscience by 1,084.5% in the 2nd quarter. Citadel Advisors LLC now owns 1,454,158 shares of the company’s stock valued at $2,457,000 after purchasing an additional 1,331,388 shares in the last quarter. Finally, BVF Inc. IL acquired a new position in shares of Aadi Bioscience in the 3rd quarter valued at approximately $33,689,000.

Aadi Bioscience Company Profile

Aadi Bioscience, Inc operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancers patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in October, 2011 and is headquartered in Los Angeles, CA.

Further Reading: What is a Fibonacci Channel?

Analyst Recommendations for Aadi Bioscience (NASDAQ:AADI)

Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.